EGEGazette
Reported
Novo Nordisk shares drop as much as 7% despite $23 billion obesity drug sales target
The decline came even as the Danish drugmaker set an ambitious sales goal for its weight-loss treatments, CNBC reported.
· 1 min read
Obesity Drugs
EGEGazette
Reported
Novo Nordisk Rebrands to 'Novo,' CEO Says Obesity Strategy Needs Rethink
In an interview with CNBC, new chief executive Mike Doustdar said the Danish drugmaker's rebranding marks a new chapter as it faces intensifying competition from Eli Lilly.
· 1 min read